New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac606 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Abubakr Mohamed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Stanford University School of Medicine, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, COVID-19, Graves Disease, Hashimoto Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Context
Occurrence of Graves’ disease (GD) has been reported following SARS-CoV-2 vaccine administration, but little is known about thyroid eye disease (TED) after SARS-CoV-2 vaccination.
Objective
We describe 2 cases of TED activation following mRNA SARS-CoV-2 vaccination and review additional cases reported in the literature.
Methods
We report 2 cases of TED activation following SARS-CoV-2 vaccination: 1 case of TED worsening in a patient with GD, and 1 of de novo active TED progressing to dysthyroid optic neuropathy in a patient with a history of Hashimoto hypothyroidism. Our literature search revealed 8 additional reported TED cases associated with SARS-CoV-2 vaccination until June 2022. We review the characteristics, duration, and management of TED following SARS-CoV-2 vaccination in these cases.
Results
Of all 10 reported TED cases following SARS-CoV-2 vaccination, 4 developed new-onset TED and 6 previously stable TED cases experienced significant deterioration. Six patients had known GD and 2 patients had Hashimoto thyroiditis. Two cases progressed to dysthyroid optic neuropathy, 6 had moderate/severe active disease, and 2 had mild disease that did not require treatment. Seven TED cases received teprotumumab and had a favorable response, 2 of whom had prior limited response to initial prednisone or methylprednisolone and tocilizumab therapy.
Conclusion
New diagnosis or deterioration of TED after mRNA SARS-CoV-2 vaccination can occur, with most cases described in patients with underlying autoimmune thyroid disease. Our report raises awareness to this potential complication to promote early recognition and prompt management of TED associated with mRNA SARS-CoV-2 vaccines. Further studies are needed to explore the mechanism, risk factors, prevention, and treatment of TED following mRNA SARS-CoV-2 vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Stanford University School of Medicine, Stanford, CA 94305, USA.
- Department of Metabolism & Experimental Therapeutics, Division of Medicine, University College London, London WC1E6DE, UK.
- Department of Endocrinology, IASO General Clinic, Athens 15123, Greece.
- Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA 94304, USA.
ORCID-Profile: Abubakr Mohamed, Chrysoula Dosiou
Zitieren
APA
Mohamed, A., Tzoulis, P., Kossler, A. L., & Dosiou, C. (2023). New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac606
Vancouver
Mohamed A, Tzoulis P, Kossler AL, Dosiou C. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac606
BibTeX
@article{Mohamed2023,
author = {Mohamed, Abubakr and Tzoulis, Ploutarchos and Kossler, Andrea Lora and Dosiou, Chrysoula},
title = {New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac606}
}
EUVIMED